Operating
Change in fair value of equity securities
Gilead Sciences Change in fair value of equity securities decreased by 43.9% to $142.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 133.3%, from -$426.00M to $142.00M. Over 2 years (FY 2021 to FY 2025), Change in fair value of equity securities shows an upward trend with a -14.0% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2017
Last reportedQ1 2026May 7, 2026
Metric ID:
intc_equity_securities_fvni_changeHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $174.00M | -$142.00M | -$291.00M | -$96.00M | -$303.00M | -$197.00M | -$61.00M | -$256.00M | -$169.00M | -$14.00M | -$391.00M | -$126.00M | -$426.00M | $142.00M | $482.00M | $253.00M | $142.00M |
| QoQ Change | — | -181.6% | -104.9% | +67.0% | -215.6% | +35.0% | +69.0% | -319.7% | +34.0% | +91.7% | <-999% | +67.8% | -238.1% | +133.3% | +239.4% | -47.5% | -43.9% |
| YoY Change | — | — | — | — | -274.1% | -38.7% | +79.0% | -166.7% | +14.2% | +94.5% | — | — | <-999% | +136.3% | — | +300.8% | +133.3% |
Range-$426.00M – $482.00M
CAGR-5.0%
Avg YoY Growth-266.4%
Median YoY Growth+46.6%
Current Streak2 quarters decline
Change in fair value of equity securities at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's change in fair value of equity securities?
- Gilead Sciences (GILD) reported change in fair value of equity securities of $142.00M in Q1 2026.
- How has Gilead Sciences's change in fair value of equity securities changed year-over-year?
- Gilead Sciences's change in fair value of equity securities increased by 133.3% year-over-year, from -$426.00M to $142.00M.
- What is the long-term trend for Gilead Sciences's change in fair value of equity securities?
- Over 2 years (2021 to 2025), Gilead Sciences's change in fair value of equity securities has grown at a -14.0% compound annual growth rate (CAGR), from -$610.00M to $451.00M.